HRP20000445B1 - Aryl fused azapolycyclic compounds - Google Patents
Aryl fused azapolycyclic compoundsInfo
- Publication number
- HRP20000445B1 HRP20000445B1 HR20000445A HRP20000445A HRP20000445B1 HR P20000445 B1 HRP20000445 B1 HR P20000445B1 HR 20000445 A HR20000445 A HR 20000445A HR P20000445 A HRP20000445 A HR P20000445A HR P20000445 B1 HRP20000445 B1 HR P20000445B1
- Authority
- HR
- Croatia
- Prior art keywords
- ring
- alkyl
- optionally substituted
- monocyclic
- carbon atoms
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 125000003118 aryl group Chemical group 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 4
- 125000002950 monocyclic group Chemical group 0.000 abstract 4
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 abstract 3
- -1 X C (= O) R 13 Chemical group 0.000 abstract 3
- 125000002619 bicyclic group Chemical group 0.000 abstract 3
- 125000004432 carbon atom Chemical group C* 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 3
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 abstract 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 abstract 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 abstract 2
- 125000001153 fluoro group Chemical group F* 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical group C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 abstract 1
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 abstract 1
- 125000005605 benzo group Chemical group 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 125000002837 carbocyclic group Chemical group 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 150000003457 sulfones Chemical class 0.000 abstract 1
- 150000003462 sulfoxides Chemical class 0.000 abstract 1
- 239000011593 sulfur Substances 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/22—Bridged ring systems
- C07D221/24—Camphidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/22—Bridged ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/08—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7024597P | 1997-12-31 | 1997-12-31 | |
| PCT/IB1998/001813 WO1999035131A1 (en) | 1997-12-31 | 1998-11-13 | Aryl fused azapolycyclic compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HRP20000445A2 HRP20000445A2 (en) | 2001-04-30 |
| HRP20000445B1 true HRP20000445B1 (en) | 2009-04-30 |
Family
ID=22094096
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20000445A HRP20000445B1 (en) | 1997-12-31 | 2000-06-30 | Aryl fused azapolycyclic compounds |
| HR20050506A HRP20050506A2 (en) | 1997-12-31 | 2005-06-07 | Aryl fused azapolycyclic compounds |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20050506A HRP20050506A2 (en) | 1997-12-31 | 2005-06-07 | Aryl fused azapolycyclic compounds |
Country Status (52)
Families Citing this family (91)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6410550B1 (en) * | 1997-12-31 | 2002-06-25 | Pfizer Inc | Aryl fused azapolycyclic compounds |
| US6605610B1 (en) * | 1997-12-31 | 2003-08-12 | Pfizer Inc | Aryl fused azapolycyclic compounds |
| US8188043B2 (en) | 1999-07-28 | 2012-05-29 | The Board Of Trustees Of The Leland Stanford Jr. University | Nicotine in therapeutic angiogenesis and vasculogenesis |
| EP1202736B1 (en) | 1999-07-28 | 2008-09-17 | The Board Of Trustees Of The Leland Stanford Junior University | Nicotine in therapeutic angiogenesis and vasculogenesis |
| IL137937A0 (en) * | 1999-08-27 | 2001-10-31 | Pfizer Prod Inc | A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal |
| US20020010192A1 (en) * | 2000-06-02 | 2002-01-24 | Coe Jotham Wadsworth | Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss |
| US20020016334A1 (en) * | 2000-07-31 | 2002-02-07 | Coe Jotham Wadsworth | Pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (ADHD) |
| AU2002234836B2 (en) * | 2001-04-20 | 2007-08-23 | Pfizer Products Inc. | Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic compounds |
| CA2446988A1 (en) * | 2001-05-14 | 2002-11-21 | Pfizer Products Inc. | The citrate salt of 5, 8, 14-triazatetracyclo(10.3.1.02,11.04.9)-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
| KR100551184B1 (ko) * | 2001-05-14 | 2006-02-13 | 화이자 프로덕츠 인크. | 5,8,14-트리아자테트라시클로[10.3.1.02,11.04,9]-헥사데카-2(11),3,5,7,9-펜타엔의 타르타르산염 및 그의 제약 조성물 |
| AU2002341327A1 (en) * | 2001-11-29 | 2003-06-10 | Pfizer Products Inc. | Succinic acid salts of 5,8,14-triazatetracyclo'10.3.1.0<2,11>.0<4,9>-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
| MXPA04003807A (es) * | 2001-11-30 | 2004-07-30 | Pfizer Prod Inc | Formulaciones farmaceuticas de 5, 7, 14-trianzatetraciclo [10.3.1.02, 11, 04, 9]-hexadeca -2 (11), 3, 5, 7, 9-pentaeno. |
| ATE405574T1 (de) | 2001-11-30 | 2008-09-15 | Pfizer Prod Inc | Aryl-annellierte azapolyzyklische verbindungen |
| US7320788B2 (en) * | 2002-02-14 | 2008-01-22 | The Board Of Trustees Of The Leland Stanford Junior University | Enzyme treatment of foodstuffs for Celiac Sprue |
| DE60336754D1 (de) * | 2002-02-14 | 2011-05-26 | Univ R | Enzymbehandlung von nahrungsmitteln für zöliakie-sprue |
| US8143210B2 (en) | 2002-02-14 | 2012-03-27 | The Board Of Trustees Of The Leland Stanford Junior University | Enzyme treatment of foodstuffs for celiac sprue |
| US7462688B2 (en) * | 2002-05-14 | 2008-12-09 | The Board Of Trustees Of The Leland Stanford Junior University | Peptides for diagnostic and therapeutic methods for celiac sprue |
| CA2487247A1 (en) * | 2002-05-14 | 2003-11-27 | The Board Of Trustees Of The Leland Stanford Junior University | Drug therapy for celiac sprue |
| US7202216B2 (en) * | 2002-05-14 | 2007-04-10 | The Board Of Trustees Of The Leland Stanford Junior University | Drug therapy for celiac sprue |
| US7265093B2 (en) * | 2002-05-14 | 2007-09-04 | The Board Of Trustees Of The Leland Stanford Junior University | Drug therapy for Celiac Sprue |
| BR0316392A (pt) | 2002-11-20 | 2005-09-27 | Pfizer Prod Inc | Processo para preparar ácido indan-1,3-dicarboxìlico |
| EP1563300B1 (en) | 2002-11-20 | 2012-04-18 | The Board Of Trustees Of The Leland Stanford Junior University | Diagnostic method for celiac sprue |
| KR100655848B1 (ko) * | 2002-11-25 | 2006-12-11 | 화이자 프로덕츠 인크. | 1,3-치환된 인덴의 개선된 제조 방법 |
| US20070066827A1 (en) * | 2003-01-15 | 2007-03-22 | Pfizer Inc. | Process for the preparation of aryl fused polycyclic lactams |
| US20040224963A1 (en) * | 2003-05-09 | 2004-11-11 | Pfizer Inc | Pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal |
| US20040224962A1 (en) * | 2003-05-09 | 2004-11-11 | Pfizer Inc | Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss |
| EP1633358A1 (en) * | 2003-05-20 | 2006-03-15 | Pfizer Products Inc. | Pharmaceutical compositions of varenicline |
| PL1638971T3 (pl) * | 2003-06-04 | 2009-01-30 | Pfizer Prod Inc | Wytwarzanie podstawionych chinoksalin z dianiliny i 2,3-dihydroksy-1,4-dioksanu |
| BRPI0412712A (pt) | 2003-07-21 | 2006-09-26 | Pfizer Prod Inc | compostos azapolicìclicos fundidos com heteroarila |
| CA2533100A1 (en) * | 2003-07-21 | 2005-01-27 | Pfizer Products Inc. | Aryl fused azapolycyclic compounds |
| US20050043407A1 (en) * | 2003-08-22 | 2005-02-24 | Pfizer Inc | Pharmaceutical composition for the prevention and treatment of addiction in a mammal |
| US20050043406A1 (en) * | 2003-08-22 | 2005-02-24 | Pfizer Inc | Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss |
| US7579313B2 (en) | 2003-11-18 | 2009-08-25 | The Board Of Trustees Of The Leland Stanford Junior University | Transglutaminase inhibitors and methods of use thereof |
| US7628985B2 (en) * | 2004-04-26 | 2009-12-08 | The Board Of Regents Of The Leland Stanford Junior University | Therapeutic enzyme formulations and uses thereof in celiac sprue and/or dermatitis herpetoformis |
| US7563864B2 (en) * | 2004-04-26 | 2009-07-21 | Celiac Sprue Research Foundation | Prolyl endopeptidase mediated destruction of T cell epitopes in whole gluten |
| US7534426B2 (en) * | 2004-04-26 | 2009-05-19 | The Board Of Trustees Of The Leland Stanford Junior University | Glutenase enzyme assays |
| WO2006006071A1 (en) * | 2004-07-07 | 2006-01-19 | Pfizer Products Inc. | Resolution of an aryl-fused azapolycyclic compound |
| US7766018B2 (en) * | 2004-09-30 | 2010-08-03 | Smoke-Break, Inc. | Device and composition for reducing the incidence of tobacco smoking |
| JP2008531540A (ja) * | 2005-02-24 | 2008-08-14 | ファイザー・プロダクツ・インク | 高純度置換キノキサリンの調製 |
| US20060211649A1 (en) * | 2005-03-21 | 2006-09-21 | Eric Marchewitz | Use of cytisine for enhancing physical performance |
| WO2007076875A2 (en) * | 2006-01-06 | 2007-07-12 | Aarhus Universitet | Compounds acting on the serotonin transporter |
| KR20090005305A (ko) * | 2006-03-27 | 2009-01-13 | 화이자 프로덕츠 인크. | 바레니클린 표준물질 및 불순물 제어 |
| BRPI0710914A2 (pt) * | 2006-04-24 | 2011-09-27 | Pfizer Prod Inc | forma de dosagem e método para o tratamento de dependência, adição e supressão de nicotina, em particular para uso na terapia para parar de fumar |
| EP2083921A2 (en) | 2006-09-04 | 2009-08-05 | Neurosearch A/S | Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer |
| AU2007319951A1 (en) * | 2006-11-09 | 2008-05-22 | Pfizer Products Inc. | Polymorphs of nicotinic intermediates |
| US8778338B2 (en) * | 2007-03-16 | 2014-07-15 | The Board Of Trustees Of The Leland Stanford Junior University | Combination enzyme therapy for digestion of dietary gluten |
| WO2009034431A2 (en) | 2007-09-10 | 2009-03-19 | Pfizer Inc. | Controlled-release dosage forms for varenicline |
| EP2260037A2 (en) * | 2008-02-15 | 2010-12-15 | Medichem, S.A. | A polymorphic form of a pyrazino [2,3-h] [3] benzazepine derivative |
| US20090215787A1 (en) * | 2008-02-22 | 2009-08-27 | Mai De Ltd. | Preparations of new polymorphic forms of varenicline tartrate |
| WO2009146031A1 (en) | 2008-03-31 | 2009-12-03 | University Of South Florida | Methods of treating disease-induced ataxia and non-ataxic imbalance |
| CA2709774C (en) | 2008-05-22 | 2012-10-02 | Teva Pharmaceutical Industries Ltd. | Varenicline tosylate, an intermediate in the preparation process of varenicline l-tartrate |
| US20090318460A1 (en) * | 2008-05-26 | 2009-12-24 | Glenmark | Amorphous varenicline tartrate and process for the preparation thereof |
| WO2009155403A2 (en) * | 2008-06-19 | 2009-12-23 | Teva Pharmaceutical Industries Ltd. | Processes for the preparation of varenicline and intermediates thereof |
| WO2010005643A1 (en) * | 2008-07-10 | 2010-01-14 | Teva Pharmaceutical Industries Ltd. | Processes for purifying varenicline l-tartrate salt and preparing crystalline forms of varenicline l-tartrate salt |
| EP2334679A1 (en) * | 2008-09-01 | 2011-06-22 | Actavis Group PTC EHF | Process for preparing varenicline, varenicline intermediates, and pharmaceutically acceptable salts thereof |
| EP2204369A1 (en) | 2008-12-22 | 2010-07-07 | Medichem, S.A. | Process for preparing varenicline and intermediates for use therein |
| KR20110132564A (ko) * | 2009-02-11 | 2011-12-08 | 선오비온 파마슈티컬스 인코포레이티드 | 히스타민 ｈ3 역 작용제 및 길항제, 및 이의 사용 방법 |
| CA2801842A1 (en) | 2009-06-10 | 2010-12-16 | Actavis Group Ptc Ehf | Amorphous varenicline tartrate co-precipitates |
| US8178537B2 (en) | 2009-06-22 | 2012-05-15 | Teva Pharmaceutical Industries Ltd. | Solid state forms of varenicline salts and processes for preparation thereof |
| CA2772525A1 (en) * | 2009-09-11 | 2011-03-17 | Sunovion Pharmaceuticals Inc. | Histamine h3 inverse agonists and antagonists and methods of use thereof |
| US20130101630A1 (en) | 2010-03-09 | 2013-04-25 | Actavis Group Ptc Ehf | Highly pure varenicline or a pharmaceutically acceptable salt thereof substantially free of methylvarenicline impurity |
| KR101109389B1 (ko) * | 2010-04-30 | 2012-01-30 | 삼성전기주식회사 | 인쇄회로기판 및 그 제조방법 |
| WO2011140431A1 (en) | 2010-05-06 | 2011-11-10 | Teva Pharmaceutical Industries Ltd. | Varenicline salts and crystal forms thereof |
| US20120004239A1 (en) | 2010-06-11 | 2012-01-05 | Medichem, S.A. | Process for Preparing Quinoxaline Derivatives |
| RU2014103098A (ru) | 2011-06-30 | 2015-08-10 | Торэй Индастриз, Инк. | Противозудный агент |
| ITMI20111413A1 (it) | 2011-07-28 | 2013-01-29 | Dipharma Francis Srl | Procedimento per la preparazione di vareniclina |
| ES2426838B1 (es) | 2012-04-20 | 2014-05-07 | Genetracer Biotech S.L | Método para predecir el éxito en el abandono del consumo de tabaco en respuesta a un tratamiento farmacológico |
| ES2426517B1 (es) | 2012-04-20 | 2014-05-14 | Genetracer Biotech S.L | Método para predecir la seguridad de un tratamiento farmacológico |
| CN103570502A (zh) * | 2012-07-18 | 2014-02-12 | 上海科胜药物研发有限公司 | 一种伐伦克林中间体的制备方法 |
| US9636340B2 (en) | 2013-11-12 | 2017-05-02 | Ayyappan K. Rajasekaran | Kinase inhibitors |
| CN103992272B (zh) * | 2014-06-09 | 2016-05-11 | 安徽省逸欣铭医药科技有限公司 | 一种盐酸喷他佐辛酯、其制备方法及其用途 |
| KR20160126697A (ko) | 2015-04-24 | 2016-11-02 | 한미정밀화학주식회사 | 신규 결정형의 바레니클린 옥살산 염 수화물, 이의 제조방법, 및 이를 포함하는 약학 조성물 |
| KR20160143407A (ko) | 2015-06-05 | 2016-12-14 | 한미정밀화학주식회사 | 신규한 바레니클린 뮤케이트 염, 이의 결정형 및 이의 제조방법 |
| KR101724301B1 (ko) | 2016-11-22 | 2017-04-10 | 주식회사 한서켐 | 바레니클린 살리실산염의 i형 결정 및 그 제조방법 |
| CN106674194B (zh) * | 2016-12-14 | 2019-03-05 | 山东省联合农药工业有限公司 | 一种结构新颖的烟碱类杀虫剂及其制备方法和用途 |
| EP3590498A4 (en) | 2017-03-03 | 2020-12-16 | CTC Bio, Inc. | PREPARATION WITH INCLUDING COMPLEX OF VARENICLINE OR PHARMACEUTICAL SAFE SALT THEREOF FOR ORAL ADMINISTRATION |
| KR102463733B1 (ko) | 2017-06-30 | 2022-11-04 | 한미약품 주식회사 | 함량 균일성 및 안정성이 향상된 바레니클린 옥살산염이 포함된 약제학적 조성물 |
| WO2018154395A2 (en) | 2018-06-11 | 2018-08-30 | Alvogen Malta Operations (Row) Ltd | Controlled release pharmaceutical composition of varenicline |
| KR20200034293A (ko) | 2018-09-21 | 2020-03-31 | 한미약품 주식회사 | 제어 방출용 바레니클린 제제 |
| WO2021222230A1 (en) | 2020-04-28 | 2021-11-04 | Oyster Point Pharma, Inc. | Local administration of nicotinic acetylcholine receptor agonists for the inhibition of coronavirus infections |
| CN113956255A (zh) * | 2020-07-20 | 2022-01-21 | 威智医药有限公司 | 一种伐尼克兰中间体、伐尼克兰及其盐的制备方法 |
| WO2022035434A1 (en) | 2020-08-14 | 2022-02-17 | Almatica Pharma Llc | Cocrystal of varenicline and oxalic acid, pharmaceutical composition thereof, and methods of use thereof |
| US11040983B1 (en) | 2020-08-14 | 2021-06-22 | Almatica Pharma Llc | Cocrystal of varenicline and oxalic acid, pharmaceutical composition thereof, and methods of use thereof |
| WO2022147189A1 (en) * | 2020-12-30 | 2022-07-07 | Antares Pharma, Inc. | Varenicline prodrugs |
| WO2022222019A1 (en) * | 2021-04-20 | 2022-10-27 | Suzhou Fude Zhaofeng Biochemical Technology Co., Ltd | Total synthesis of varenicline |
| CN113277993B (zh) * | 2021-06-06 | 2023-07-21 | 湖南第一师范学院 | 一种Tafamidis及其衍生物的合成方法 |
| WO2023275413A2 (en) | 2021-12-23 | 2023-01-05 | Medichem, S.A. | Solid pharmaceutical formulations of varenicline |
| US11602537B2 (en) | 2022-03-11 | 2023-03-14 | Par Pharmaceutical, Inc. | Varenicline compound and process of manufacture thereof |
| EP4241775A1 (en) | 2022-03-11 | 2023-09-13 | Par Pharmaceutical, Inc. | Tablet comprising varenicline and process of preparation thereof |
| WO2023244574A1 (en) | 2022-06-14 | 2023-12-21 | Amygdala Neurosciences, Inc. | Aldh-2 inhibitor compounds and methods of use |
| WO2024095172A1 (en) | 2022-11-04 | 2024-05-10 | Pfizer Inc. | Prodrugs of varenicline and compounds containing vulnerable amines |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3471503A (en) * | 1967-05-05 | 1969-10-07 | Mcneilab Inc | 1,2,3,5,6,7-hexahydro-4-phenethyl-2,6-methano-4h-4- benzazonin-12-ols |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH644116A5 (de) * | 1980-08-21 | 1984-07-13 | Hoffmann La Roche | Imidazolderivate. |
| EP0853621A1 (en) † | 1995-09-22 | 1998-07-22 | Novo Nordisk A/S | Novel substituted azacyclic or azabicyclic compounds |
| US6605610B1 (en) * | 1997-12-31 | 2003-08-12 | Pfizer Inc | Aryl fused azapolycyclic compounds |
| US6410550B1 (en) * | 1997-12-31 | 2002-06-25 | Pfizer Inc | Aryl fused azapolycyclic compounds |
| WO1999042461A1 (en) * | 1998-02-23 | 1999-08-26 | Warner-Lambert Company | Substituted quinoxaline derivatives as interleukin-8 receptor antagonists |
| EP0955301A3 (en) * | 1998-04-27 | 2001-04-18 | Pfizer Products Inc. | 7-aza-bicyclo[2.2.1]-heptane derivatives, their preparation and use according to their affinity for neuronal nicotinic acetylcholine receptors |
| PT1076650E (pt) * | 1998-04-29 | 2004-05-31 | Pfizer Prod Inc | Compostos azapoliciclicos fundidos com arilo |
| EP1147112B1 (en) * | 1999-01-29 | 2003-10-29 | Abbott Laboratories | Diazabicyclic derivatives as nicotinic acetylcholine receptor ligands |
| FR2788982B1 (fr) * | 1999-02-02 | 2002-08-02 | Synthelabo | Compositions pharmaceutiques contenant de la nicotine et leur application dans le sevrage tabagique |
| IL137937A0 (en) * | 1999-08-27 | 2001-10-31 | Pfizer Prod Inc | A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal |
| KR100551184B1 (ko) * | 2001-05-14 | 2006-02-13 | 화이자 프로덕츠 인크. | 5,8,14-트리아자테트라시클로[10.3.1.02,11.04,9]-헥사데카-2(11),3,5,7,9-펜타엔의 타르타르산염 및 그의 제약 조성물 |
| CA2446988A1 (en) * | 2001-05-14 | 2002-11-21 | Pfizer Products Inc. | The citrate salt of 5, 8, 14-triazatetracyclo(10.3.1.02,11.04.9)-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
| AU2002341327A1 (en) * | 2001-11-29 | 2003-06-10 | Pfizer Products Inc. | Succinic acid salts of 5,8,14-triazatetracyclo'10.3.1.0<2,11>.0<4,9>-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
| MXPA04003807A (es) * | 2001-11-30 | 2004-07-30 | Pfizer Prod Inc | Formulaciones farmaceuticas de 5, 7, 14-trianzatetraciclo [10.3.1.02, 11, 04, 9]-hexadeca -2 (11), 3, 5, 7, 9-pentaeno. |
| ATE405574T1 (de) * | 2001-11-30 | 2008-09-15 | Pfizer Prod Inc | Aryl-annellierte azapolyzyklische verbindungen |
| CA2533100A1 (en) * | 2003-07-21 | 2005-01-27 | Pfizer Products Inc. | Aryl fused azapolycyclic compounds |
-
1998
- 1998-11-13 US US09/402,010 patent/US6410550B1/en not_active Expired - Lifetime
- 1998-11-13 DE DE122008000038C patent/DE122008000038I1/de active Pending
- 1998-11-13 PT PT98950274T patent/PT1044189E/pt unknown
- 1998-11-13 ME MEP-2008-702A patent/ME00459B/me unknown
- 1998-11-13 JP JP2000527532A patent/JP3550359B2/ja not_active Expired - Lifetime
- 1998-11-13 DE DE69839131.4T patent/DE69839131T3/de not_active Expired - Lifetime
- 1998-11-13 AT AT98950274T patent/ATE386024T1/de active
- 1998-11-13 CN CNA2005100821428A patent/CN1715280A/zh active Pending
- 1998-11-13 CZ CZ20002438A patent/CZ301925B6/cs not_active IP Right Cessation
- 1998-11-13 ES ES98950274.5T patent/ES2301210T5/es not_active Expired - Lifetime
- 1998-11-13 UA UA2000063807A patent/UA66825C2/uk unknown
- 1998-11-13 EP EP98950274.5A patent/EP1044189B2/en not_active Expired - Lifetime
- 1998-11-13 SK SK971-2000A patent/SK286886B6/sk not_active IP Right Cessation
- 1998-11-13 BR BRPI9816186-5A patent/BR9816186B1/pt not_active IP Right Cessation
- 1998-11-13 PL PL341824A patent/PL209404B1/pl unknown
- 1998-11-13 EP EP05106853A patent/EP1659114A3/en not_active Withdrawn
- 1998-11-13 CN CNB988128195A patent/CN1324013C/zh not_active Expired - Lifetime
- 1998-11-13 NZ NZ504482A patent/NZ504482A/xx not_active IP Right Cessation
- 1998-11-13 DK DK98950274T patent/DK1044189T4/en active
- 1998-11-13 SG SG200203917A patent/SG102686A1/en unknown
- 1998-11-13 RS YUP-403/00A patent/RS50069B/sr unknown
- 1998-11-13 EA EA200000592A patent/EA003190B1/ru not_active IP Right Cessation
- 1998-11-13 AU AU96416/98A patent/AU753389C/en not_active Expired
- 1998-11-13 HU HU0100949A patent/HU230297B1/hu active Protection Beyond IP Right Term
- 1998-11-13 WO PCT/IB1998/001813 patent/WO1999035131A1/en active IP Right Grant
- 1998-11-13 TR TR2000/01840T patent/TR200001840T2/xx unknown
- 1998-11-13 BR BRPI9814592-4A patent/BR9814592B1/pt not_active IP Right Cessation
- 1998-11-13 KR KR10-2000-7007379A patent/KR100408138B1/ko active IP Right Review Request
- 1998-11-13 SI SI9830902T patent/SI1044189T2/sl unknown
- 1998-11-13 CA CA002316921A patent/CA2316921C/en not_active Expired - Lifetime
- 1998-11-13 IL IL13672798A patent/IL136727A0/xx active Protection Beyond IP Right Term
- 1998-11-19 HN HN1998000177A patent/HN1998000177A/es unknown
- 1998-11-30 CO CO98070723A patent/CO4810373A1/es unknown
- 1998-11-30 PA PA19988463901A patent/PA8463901A1/es unknown
- 1998-12-15 GT GT199800200A patent/GT199800200A/es unknown
- 1998-12-15 GT GT199800200AK patent/GT199800200AA/es unknown
- 1998-12-17 AP APAP/P/1998/001422A patent/AP1170A/en active
- 1998-12-28 EG EG161298A patent/EG23816A/xx active
- 1998-12-28 TW TW087121748A patent/TW513412B/zh not_active IP Right Cessation
- 1998-12-28 PE PE1998001286A patent/PE20000053A1/es not_active IP Right Cessation
- 1998-12-29 AR ARP980106715A patent/AR017967A1/es active IP Right Grant
- 1998-12-29 ZA ZA9811911A patent/ZA9811911B/xx unknown
- 1998-12-30 MA MA25409A patent/MA26589A1/fr unknown
- 1998-12-30 TN TNTNSN98237A patent/TNSN98237A1/fr unknown
- 1998-12-30 DZ DZ980307A patent/DZ2697A1/xx active
- 1998-12-30 MY MYPI98005949A patent/MY118163A/en unknown
-
1999
- 1999-02-28 SA SA99191123A patent/SA99191123B1/ar unknown
-
2000
- 2000-05-26 IS IS5514A patent/IS5514A/is unknown
- 2000-06-12 IL IL136727A patent/IL136727A/en active Protection Beyond IP Right Term
- 2000-06-16 OA OA1200000175A patent/OA11428A/en unknown
- 2000-06-27 BG BG104561A patent/BG65058B1/bg unknown
- 2000-06-30 NO NO20003422A patent/NO319115B1/no not_active IP Right Cessation
- 2000-06-30 HR HR20000445A patent/HRP20000445B1/xx not_active IP Right Cessation
-
2001
- 2001-04-09 HK HK01102476A patent/HK1031878A1/xx not_active IP Right Cessation
-
2002
- 2002-02-13 US US10/075,843 patent/US6887884B2/en not_active Expired - Fee Related
- 2002-02-14 US US10/075,348 patent/US20020072524A1/en not_active Abandoned
- 2002-04-22 US US10/127,267 patent/US6951938B2/en not_active Expired - Lifetime
- 2002-04-23 US US10/131,278 patent/US6897310B2/en not_active Expired - Lifetime
-
2005
- 2005-06-07 HR HR20050506A patent/HRP20050506A2/hr not_active Application Discontinuation
-
2006
- 2006-11-17 NO NO2006016C patent/NO2006016I1/no not_active IP Right Cessation
-
2007
- 2007-07-17 US US11/778,890 patent/US20070275973A1/en not_active Abandoned
-
2008
- 2008-04-14 CY CY20081100397T patent/CY1107391T1/el unknown
- 2008-05-21 LU LU91442C patent/LU91442I2/fr unknown
- 2008-06-05 NL NL300355C patent/NL300355I2/nl unknown
- 2008-07-03 CY CY200800013C patent/CY2008013I2/el unknown
- 2008-07-21 FR FR08C0039C patent/FR08C0039I2/fr active Active
-
2016
- 2016-04-27 HU HUS1600018C patent/HUS1600018I1/hu unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3471503A (en) * | 1967-05-05 | 1969-10-07 | Mcneilab Inc | 1,2,3,5,6,7-hexahydro-4-phenethyl-2,6-methano-4h-4- benzazonin-12-ols |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20000445B1 (en) | Aryl fused azapolycyclic compounds | |
| DE60015927D1 (en) | Phenylharnstoff und phenylthioharnstoffderivate | |
| AR031680A1 (es) | Utilizacion de acrilamidas de quinuclidina para la preparacion de medicamentos, compuestos y composicion farmaceutica | |
| HRP20000854B1 (en) | Therapeutic biaryl derivatives | |
| NL960021I2 (nl) | Nieuwe trifenylalkaan en alkeenderivaten den de bereiding en toepassing daarvan. | |
| UY27357A1 (es) | Nuevos agentes antidiabéticos . | |
| AR064517A1 (es) | Pirimidinionas biciclicas y sus usos | |
| MXPA00006605A (es) | Compuestos de carbonil-indol biciclicos como agentes antiinflamatorios/analgesicos. | |
| MX9302169A (es) | Fenoxialquilisoxazolas de 1,2,4-oxadiazolilo y su uso como agentes antivirales. | |
| NO20025641D0 (no) | Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister | |
| BR9509629A (pt) | Derivados de aminotetrazol úteis como inibidores de óxido nítrico sintase | |
| DE3868301D1 (de) | 2-(methyl(4-piperidinyl))-1,2,3,4-tetrahydro-9h-pyrido(3,4-b)indolderivate, ihre herstellung und therapeutische verwendung. | |
| NO20025640D0 (no) | Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister | |
| PE20040757A1 (es) | Derivados de benzoxazina | |
| PE14696A1 (es) | Derivado de fenetanolamina | |
| AR007108A1 (es) | Agentes antitumorales y antivirales alquilantes, procedimiento para su preparacion, utilizacion de los mismos para la fabricacion de un medicamento y composicion farmaceutica que contiene a dichos agentes. | |
| RS50289B (sr) | Novi razgranati supstituisani amino derivati od 3-amino-1- fenil-1h(1,2,4) triazola, postupak za njihovo dobijanje i farmaceutski preparati koji ih sadrže | |
| PT75602A (fr) | Procede de preparation de nouvelles triazoloquinazolones et de leurs sels | |
| DK0612314T3 (da) | 2-pyrazinylethylaminderivater og deres anvendelse som lægemidler | |
| DK1163258T3 (da) | Derivater af 22R-hydroxycholesta-8, 14-dien til inhiberingen af meiosis | |
| UY26147A1 (es) | Derivados de 1-trifluorometil-4-hidroxi-7-piperidinil-aminometilcromano. | |
| DK1049672T3 (da) | Azetidincarboxamid-derivater til behandling af CNS-lidelser | |
| ES2182770T3 (es) | "n-(pieridin-4-il)-4h-3,1 benzo(tia/oxa)zinas-2-aminas substituidas, su preparacion y su aplicacion en terapeutica. | |
| FR2788771B1 (fr) | Nouvelles 1,2-alcoyl-1-[1-[aryl (alcoyl) oxyalcoyl] piperidin-4-yl]-3-aryl isothiourees substituees, leur preparation et leur application en therapeutique | |
| AR031763A1 (es) | Nuevos compuestos para el uso como inhibidores de proteasas hiv |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1OB | Publication of a patent application | ||
| ARAI | Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application | ||
| B1PR | Patent granted | ||
| ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20171109 Year of fee payment: 20 |
|
| PB20 | Patent expired after termination of 20 years |
Effective date: 20181113 |